Replies to post #17777 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

After copax…do you see that next value-creating event as market approval for the Orencia copy?

No, M834 (Orencia FoB) is just finishing up phase-1, while M923 (Humira FoB) is nearly ready for submission of the 351(k) BLA. So, M923 is 1-2 years ahead of M834.

Moreover, there are various milestones in MNTA’s autoimmune programs that will precede FDA approval of M834. Please see the immediately following news flow post for details. Regards, Dew